Drug intelligence / Profile preview

GBS-CP139

Development stage: Preclinical
Lead developer: Gb Sciences
Modality: Small Molecules

Overview

GBS-CP139 is a chemical drug candidate developed by GB Sciences, Inc. It is being investigated for the treatment of chronic pain, specifically within the therapeutic area of nervous system diseases. As of March 2025, its highest development status is preclinical. Detailed information about its mechanism of action or molecular targets has not been disclosed publicly[1].

Other names: oral nanoparticle cannabinoid/phytochemical formulation

Beyond the preview

Go deeper on GBS-CP139.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GBS-CP139.

Explore the full profile